Clinical TrialApr 21, 2026, 05:31 PM
Zymeworks ZW191 Phase 1 Shows 61% cORR in Ovarian Cancer
AI Summary
Zymeworks announced encouraging Phase 1 results for ZW191, an FR-targeting ADC, in heavily pretreated ovarian and endometrial cancers. The study showed a confirmed objective response rate (cORR) of 61% in platinum-resistant ovarian cancer at optimal doses, with a median progression-free survival of 7.6 months. The drug demonstrated a favorable tolerability profile and activity across varying levels of FR expression, supporting its potential as a best-in-class agent and warranting further clinical development.
Key Highlights
- ZW191 showed 61% cORR in platinum-resistant ovarian cancer at 6.4-9.6 mg/kg.
- Median progression-free survival was 7.6 months in ovarian and endometrial cancers.
- Median duration of response was not reached at data cutoff.
- Severe (grade ">3") TEAEs occurred in 55% of patients, mostly grade 3.
- ZW191 demonstrated 57% cORR in endometrial cancer at 6.4-9.6 mg/kg.